This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Woo, M. H. Articles by Relling, M. V. Search for Related Content PubMed PubMed Citation Articles by Woo, M. H. Articles by Relling, M. V. Social Bookmarking                            What's this?

Hypersensitivity or Development of Antibodies to Asparaginase Does Not Impact Treatment Outcome of Childhood Acute Lymphoblastic Leukemia

From the Departments of Pharmaceutical Sciences, Hematology-Oncology, and Biostatistics and Epidemiology, St. Jude Children’s Research Hospital, and Colleges of Pharmacy and Medicine, University of Tennessee, Memphis, TN.

Address reprint requests to Mary V. Relling, PharmD, Pharmaceutical Department, St. Jude Children’s Research Hospital, 332 N Lauderdale, Memphis, TN 38105; email mary.relling{at}stjude.org

PURPOSE: Development of antibodies and hypersensitivity to asparaginase are common and may attenuate asparaginase effect. Our aim was to determine the relationship between antiasparaginase antibodies or hypersensitivity reactions and event-free survival (EFS).

PATIENTS AND METHODS: One hundred fifty-four children with acute lymphoblastic leukemia received Escherichia coli asparaginase 10,000 IU/m² intramuscularly three times weekly for nine doses during multiagent induction and reinduction phases and for seven monthly doses during continuation treatment. Erwinia asparaginase was used in case of clinical hypersensitivity to E coli but not for subclinical development of antibodies. Plasma antiasparaginase antibody concentrations were measured on day 29 of induction in 152 patients.

RESULTS: Antibodies were detectable in 54 patients (35.5%), of whom 30 (55.6%) exhibited hypersensitivity to asparaginase. Of the 98 patients who had no detectable antibodies, 18 (18.4%) had allergic reactions. Patients with antibodies were more likely to have a reaction than those without antibodies (P < .001). Among the 50 patients who experienced allergic reactions (including two for whom antibodies were not measured), 36 (72.0%) were subsequently given Erwinia asparaginase; seven (19.4%) reacted to this preparation. EFS did not differ among patients who did and did not have antibodies (P = .54), with 4-year EFS (± 1 SE) of 83% ± 6% and 76% ± 5%, respectively. Similarly, EFS did not differ among patients who did and did not develop allergic reactions (P = .68), with 4-year estimates of 82% ± 6% and 78% ± 5%, respectively.

CONCLUSION: In this setting, in which most patients with allergy were switched to another preparation, there was no adverse prognostic impact of clinical or subclinical allergy to asparaginase.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L. B. Silverman, J. G. Supko, K. E. Stevenson, C. Woodward, L. M. Vrooman, D. S. Neuberg, B. L. Asselin, U. H. Athale, L. Clavell, P. D. Cole, et al. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia Blood, February 18, 2010; 115(7): 1351 - 1353. [Abstract] [Full Text] [PDF]

				V. I. AVRAMIS, E. V. AVRAMIS, W. HUNTER, and M. C. LONG Immunogenicity of Native or Pegylated E. coli and Erwinia Asparaginases Assessed by ELISA and Surface Plasmon Resonance (SPR-Biacore) Assays of IgG Antibodies (Ab) in Sera from Patients with Acute Lymphoblastic Leukemia (ALL) Anticancer Res, January 1, 2009; 29(1): 299 - 302. [Abstract] [Full Text] [PDF]

				D. Douer, H. Yampolsky, L. J. Cohen, K. Watkins, A. M. Levine, A. P. Periclou, and V. I. Avramis Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia Blood, April 1, 2007; 109(7): 2744 - 2750. [Abstract] [Full Text] [PDF]

				M. Duval, S. Suciu, A. Ferster, X. Rialland, B. Nelken, P. Lutz, Y. Benoit, A. Robert, A.-M. Manel, E. Vilmer, et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer---Children's Leukemia Group phase 3 trial Blood, April 15, 2002; 99(8): 2734 - 2739. [Abstract] [Full Text] [PDF]

				V. I. Avramis, S. Sencer, A. P. Periclou, H. Sather, B. C. Bostrom, L. J. Cohen, A. G. Ettinger, L. J. Ettinger, J. Franklin, P. S. Gaynon, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study Blood, March 15, 2002; 99(6): 1986 - 1994. [Abstract] [Full Text] [PDF]

				B. M. Bickert Treatment of Common Childhood Malignancies Journal of Pharmacy Practice, February 1, 2002; 15(1): 42 - 51. [Abstract] [PDF]